Subcutaneous administration of anti-CD38 antibodies
US12371506B2 · kind B2 · utility
0Cited by
23References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2019 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | May 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of administering isolated anti-CD38 antibodies at low dosages subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.